[{"id":"c3c05277-42e5-4669-bea5-688ad1660501","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001658","created_at":"2023-08-21T14:08:46.484Z","updated_at":"2025-02-25T16:19:01.820Z","phase":"Phase 2","brief_title":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","source_id_and_acronym":"NCT06001658","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD163 • CD68","pipe":" | ","alterations":" ARG1 overexpression • CD163 expression","tags":["CD8 • CD163 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARG1 overexpression • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-25"},{"id":"3a511d5d-3245-4fbd-a2c8-a89db4e723ed","acronym":"CIFRA","url":"https://clinicaltrials.gov/study/NCT03874026","created_at":"2021-01-18T19:06:05.689Z","updated_at":"2024-07-02T16:35:12.803Z","phase":"Phase 2","brief_title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","source_id_and_acronym":"NCT03874026 - CIFRA","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression","tags":["KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 05/19/2023","primary_completion_date":" 05/19/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-26"},{"id":"495ae210-14e3-4dc2-9bda-5e696bcb61a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056804","created_at":"2023-11-19T01:16:40.961Z","updated_at":"2024-07-02T16:35:28.894Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","source_id_and_acronym":"NCT06056804","lead_sponsor":"Beijing Friendship Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":" | ","alterations":" CD163 expression • CD4 expression","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-17"},{"id":"7a5d5274-188b-454f-a274-136cb9718498","acronym":"","url":"https://clinicaltrials.gov/study/NCT01494688","created_at":"2021-01-18T06:15:43.986Z","updated_at":"2024-07-02T16:37:12.988Z","phase":"Phase 1a/1b","brief_title":"A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT01494688","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD163 • CD68 • CSF1R","pipe":" | ","alterations":" CD163 expression","tags":["CD163 • CD68 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • emactuzumab (RG7155)"],"overall_status":"Completed","enrollment":" Enrollment 217","initiation":"Initiation: 12/20/2011","start_date":" 12/20/2011","primary_txt":" Primary completion: 02/07/2018","primary_completion_date":" 02/07/2018","study_txt":" Completion: 02/07/2018","study_completion_date":" 02/07/2018","last_update_posted":"2018-03-16"}]